A Clinical Study to Assess the Efficacy and Safety of DA-3002

Summary

A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin®.

Timeline

Start

2013-02

Primary completion

2018-05

Completion

2018-05

Outcome

Met primary endpoint

paper The lower bound of 95% two-sided confidence interval for group difference in the change of annualized HV (- 1.02) satisfied the non-inferiority margin (- 1.5). PMID 34893062 ↗

Publications

• Kim J, Kim MS, Suh BK, Ko CW, Lee KH, Yoo HW, Shin CH, Hwang JS, Kim HS, Chung WY, Kim CJ, Han HS, Jin DK. Recombinant growth hormone therapy in children with Turner Syndrome in Korea: a phase III Randomized Trial. BMC Endocr Disord. 2021 Dec 10;21(1):243. doi: 10.1186/s12902-021-00904-5.

Drugs

Indications